Publications by authors named "K Kashiwabara"
Objectives: Rituximab is emerging as a promising therapeutic option for systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, little is known about factors that predict the efficacy of rituximab in SSc-ILD.
Methods: A post-hoc analysis was performed on prospective data from 48 patients with SSc-ILD in the double-blind, randomized, placebo-controlled DESIRES trial.
Background: Concurrent chemoradiotherapy is the standard therapy for locally advanced non-small cell lung cancer (NSCLC). However, there is little evidence supporting its use in older adults. Low-dose daily carboplatin combined with thoracic radiotherapy is considered a standard regimen for this population.
View Article and Find Full Text PDFBackground: Granulocyte colony-stimulating factor (G-CSF)-producing tumors have been reported in various organs, and the prognosis of patients with G-CSF-producing pancreatic cancers is particularly dismal. In this report, we present a case of G-CSF-producing anaplastic carcinoma of the pancreas (ACP), characterized by early postoperative recurrence and rapid, uncontrolled growth.
Case Presentation: A 74-year-old man presented to our hospital with complaints of abdominal fullness and pain after eating.
Article Synopsis
- The WONDER-02 trial is a randomized controlled study aimed at comparing the effectiveness of plastic stents versus lumen-apposing metal stents (LAMSs) for treating symptomatic pancreatic pseudocysts through endoscopic ultrasound (EUS) drainage.
- The trial will enroll 80 patients from 26 centers in Japan, dividing them into two groups of 40 to receive either type of stent and assessing outcomes like pseudocyst size reduction and overall health improvements.
- The results will help determine if plastic stents are just as effective as LAMSs, potentially influencing future treatment guidelines for pancreatic pseudocyst patients.
Article Synopsis
- Eribulin, a treatment for HER2-negative metastatic breast cancer, shows promising outcomes for overall survival when used as a first or second-line therapy, although its effect on health-related quality of life remains to be fully understood.
- A phase III clinical trial conducted in Japan enrolled 302 patients and compared the HRQoL and survival outcomes between those treated with eribulin and those treated with S-1, revealing a slight non-inferiority in HRQoL and longer median overall survival for eribulin.
- Results indicated a median overall survival of 34.7 months for eribulin compared to 27.8 months for S-1, with eribulin also showing similar progression-free survival